Heartflow (HTFL) announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association, AHA, Scientific Sessions 2025. The new data add to the growing body of evidence supporting AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging – the most clinically validated framework for actionable CAD care. Key findings include: Patients in the highest TPV stage experienced more than a 5x greater risk of major cardiovascular events compared with patients in the lowest stage. Higher plaque volume stages were independently associated with significantly increased rates of cardiovascular death and myocardial infarction over a median 3.3 years of follow-up. Associations remained significant after adjustment for coronary stenosis, FFRCT values and cardiovascular risk factors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- HeartFlow’s Innovative Study on Cardiac Risk in NFL Alumni: A Potential Game-Changer
- HeartFlow’s COMPLETE Study: A New Frontier in Coronary Artery Disease Evaluation
- Heartflow introduces Heartflow PCI Navigator
- Heartflow announces FDA clearance of plaque analysis algorithm, Cigna coverage
- Heartflow price target raised to $39 from $35 at Canaccord